
SPDR MSCI Europe Health Care UCITS ETF
SPDR MSCI Europe Health Care UCITS ETF (GB:HLTH) Price & Chart
GB:HLTH ETF Chart & Stats
- Day’s Range
- EUR 248.00 - EUR 249.90
- 52-Week Range
- EUR 210.50 - EUR 261.50
- Previous Close
- EUR 248.95
- Volume
- 5,841
- Average Volume (3M)
- 2,983
- AUM
- 636.40M
- NAV
- 248.96
- Expense Ratio
- 0.20%
- Holdings Count
- 39
- Beta
- 0.99
- Inception Date
- Dec 05, 2014
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 2,589,300
- Standard Deviation
- N/A
ETF Overview
SPDR MSCI Europe Health Care UCITS ETF
The SPDR MSCI Europe Health Care UCITS ETF, with the ticker SSHXF, is a compelling investment vehicle designed for those looking to capitalize on the robust and dynamic health care sector within Europe. As a sector-focused ETF, SSHXF offers investors targeted exposure to a diverse array of companies operating in the European health care industry, encompassing pharmaceuticals, biotechnology, medical devices, and health care services. This ETF stands out in its broad-based niche by providing a comprehensive representation of the health care segment, allowing investors to tap into the innovative and essential services that drive this critical sector. With Europe being home to some of the leading health care companies globally, SSHXF presents a unique opportunity for investors to benefit from the region's advancements and market growth. This ETF is ideal for those seeking to enhance their portfolio with a focus on health care, offering both diversification and the potential for significant returns driven by the ongoing demand for health care solutions and innovations in the European market.
- Asset Class
- Equity
- Region
- Europe
- Issuer
- SPDR
- Index Tracked
- MSCI Europe Health Care 35/20 Capped Index - EUR - Benchmark TR Net
- Ticker Symbol
- GB:HLTH
GB:HLTH ETF News




AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s GRACE-DE study, officially titled “Prospective, Observational, Multicenter, and Multicohort Study of Patients With Gastric Cancer Initiating









